Related Experiment Video
Updated: Jul 21, 2025

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
Published on: October 23, 2019
Emerging trends in IRAK-4 kinase research
Himanshu Yadav1, Raj Kumar Shirumalla2
1SGT College of Pharmacy, SGT University, Budhera, Gurugram, Haryana, 122505, India.
Abstract:
The IRAK-4 kinase lies at a critical signaling node that drives cancer cell survival through multiple mechanisms, activation, and translocation of NF-κB mediated inflammatory responses and innate immune signaling through regulation of interferon-α/β receptor (IFNα/β). Inhibition, of IRAK-4, has consequently drawn a lot of attention in recent years to address indications ranging from oncology to autoimmune disorders to neurodegeneration, etc. However, the key stumbling block in targeting IRAK-4 is that despite the inhibition of the kinase activity using an inhibitor the target remains effective, reducing the potential of an inhibitor. This is due to the "scaffolding effect" because of which although regulation of downstream processes by IRAK-4 has been primarily linked with kinase function; however, still, various reports have suggested that IRAK-4 has a non-kinase function in a variety of cell types. This is attributed to the myddosome complex formed by IRAK-4 with myd88, IRAK-2, and IRAK-1 which by itself can cause the activation of downstream effector TRAF6 despite inhibition of the kinase domain of IRAK-4. With this challenge, several groups initiated the development of targeting protein degraders of IRAK-4 using Proteolysis-Targeting Chimeras (PROTACs) technology to completely remove the IRAK-4 from the cellular milieu. In this review, we will capture all these developments and the evolving science around this target.
Insights
Targeting IRAK-4 (interleukin-1 receptor-associated kinase 4) is crucial for treating various diseases. However, its scaffolding effect limits traditional inhibitors, prompting the development of Proteolysis-Targeting Chimeras (PROTACs) for complete IRAK-4 degradation.
Area of Science:
- Biochemistry
- Molecular Biology
- Immunology
Background:
- Interleukin-1 receptor-associated kinase 4 (IRAK-4) is a key kinase in signaling pathways.
- IRAK-4 regulates NF-κB and innate immune responses, impacting cancer, autoimmune, and neurodegenerative diseases.
- Traditional IRAK-4 kinase inhibitors face limitations due to the protein's scaffolding function.
Purpose of the Study:
- To review the challenges in targeting IRAK-4 kinase activity.
- To explore the development of Proteolysis-Targeting Chimeras (PROTACs) for IRAK-4 degradation.
- To discuss the evolving science and therapeutic potential of targeting IRAK-4.
Main Methods:
- Literature review of IRAK-4 signaling and inhibition strategies.
- Analysis of the scaffolding role of IRAK-4 in cellular processes.
- Examination of PROTAC technology applied to IRAK-4 targeting.
Main Results:
- IRAK-4's non-kinase scaffolding function, particularly within the myddosome complex, contributes to its persistent activity.
- The myddosome complex can activate downstream effectors like TRAF6 independently of IRAK-4's kinase domain.
- PROTACs offer a novel approach to overcome resistance by inducing complete IRAK-4 degradation.
Conclusions:
- Targeting IRAK-4's scaffolding function is essential for effective therapeutic intervention.
- PROTACs represent a promising strategy to overcome the limitations of traditional IRAK-4 inhibitors.
- Further research into IRAK-4 degradation holds significant therapeutic potential across multiple disease areas.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
MAPK Signaling Cascades
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Amplifying Signals via Enzymatic Cascade
The JAK-STAT Signaling Pathway
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...

